IN THE CLAIMS

Please amend the status of the claims, as presented in Applicant's concurrently-filed *Literal English Translation of P.C.T. Application No. PCT/DE2004/002503*, as indicated below:

Claims 1-26 (canceled)

27. (new) A purified polypeptide, comprising:

an amino acid sequence substantially identical to the amino acid sequence of the group consisting of SEQ ID NO:1, SEQ ID:3 and a combination thereof, said polypeptide being capable of binding at least one of low density lipoproteins (LDL) and oxidized LDL (oxLDL).

28. (new) The purified polypeptide according to Claim 27, wherein said polypeptide is capable of binding at least one of LDL cholesterol and oxidized LDL cholesterol (oxLDL cholesterol).

29. (new) The purified polypeptide according to Claim 27, wherein said polypeptide or a fragment thereof and the low density lipoproteins (LDL) and low density lipoproteins (oxLDL) occurring in human and other animal bodies have complementary carbohydrate structures.

30. (new) The purified polypeptide according to Claim 27, wherein said polypeptide is an antibody or a functional fragment of said antibody.

31. (new) The purified polypeptide according to Claim 27, wherein said polypeptide is a functional fragment of a member selected from the group consisting of V_L, V_H, F_V, F_C, Fab, Fab' and $F(ab')_2$.

32. (new) The purified polypeptide according to Claim 31, wherein said polypeptide includes an amino acid sequence of a variable region of the light chain (V_L) is substantially identical to SEQ ID NO:1, an amino acid sequence of a variable region of the heavy chain (V_H) is substantially identical to SEQ ID NO:3, or both said amino acid sequences of said variable regions of said light chain (V_L) and said heavy chain (V_H).

33. (new) The purified polypeptide according to Claim 31, wherein said polypeptide includes a nucleic acid sequence of a variable region of the light chain (V_L) is substantially identical to SEQ ID NO:2, a nucleic acid sequence of a variable region of the heavy chain (V_H) is substantially identical to SEQ ID NO:4, or both said nucleic acid sequences of said variable regions of said light chain (V_L) and said heavy chain (V_H).

34. (new) The purified polypeptide according to Claim 31, wherein said functional fragment contains an amino acid fragment of the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3.

35. (new) The purified polypeptide according to Claim 31, wherein said functional fragment contains an amino acid sequence fragment that is substantially identical the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:3.

36. (new) The purified polypeptide according to Claim 27, wherein said polypeptide is substantially identical to the amino acid sequence of SEQ ID NO:1.

37. (new) The purified polypeptide according to Claim 27, wherein said polypeptide is substantially identical to the amino acid sequence of SEQ ID NO:3.

38. (new) The purified polypeptide according to Claim 27, wherein said polypeptide contains nucleic acid sequences that are substantially identical to the nucleotides 67-69 (CDR1), 145-165 (CDR2) and 262-288 (CDR3) of SEQ ID NO:2.

39. (new) The purified polypeptide according to Claim 27, wherein said polypeptide contains nucleic acid sequences that are substantially identical to the nucleotides 91-105 (CDR1), 148-198 (CDR2) and 295-330 (CDR3) of SEQ ID NO:4.

40. (new) The purified polypeptide according to Claim 27, wherein said polypeptide is a monoclonal antibody.

41. (new) The purified polypeptide according to Claim 27, wherein said polypeptide is a hybridoma.

42. (new) A purified polypeptide comprising an amino acid sequence selected from the group consisting of the amino acid sequence of SEQ ID NO:1, the amino acid sequence of SEQ ID NO:3 and a combination thereof.

43. (new) A complementary-determining region (CDR), or a functional fragment of said complementary-determining region, comprising an amino acid sequence selected from the group consisting of [Ser-Gly-Asp-Lys-Leu-Gly-Asp-Lys-Tyr-Ala-Cys (CDR1) or Gln-Asp-Ser-Lys-Arg-Pro-Ser (CDR2) or Gln-Ala-Trp-Asp-Ser-Ser-Ile-Val-Val (CDR3) of SEQ ID NO:1], [Ser-Tyr-Ala-Met-His (CDR1) or Val-Ile-Ser-Tyr-Asp-Gly-Ser-Asn-Lys-Tyr-Tyr-Ala-Asp-Ser-Val-Lys-Gly (CDR2) or Asp-Arg-Leu-Ala-Val-Ala-Gly-Lys-Thr-Phe-Asp-Tyr (CDR3) of SEQ ID NO:3.] and a combination thereof.

44. (new) A method for generating an antibody, comprising the steps of:

obtaining B-lymphocytes from a spleen, lymph nodes or blood of a human being; and,

fusing heteromyeloma cells HAB-1and subclones thereof with B-lymphocytes, thereby obtaining hybridoma cells for use as an antibody.

45. (new) The method for generating an antibody according to Claim 44, wherein said antibody is a purified polypeptide.

46. (new) The antibody produced according to the method of Claim 44.

47. (new) The purified polypeptide produced according to Claim 45.